Skip to main content

Table 1 Baseline characteristics of patients with AM who received TACE+RFA or TACE alone

From: Clinical efficacy of chemoembolization with simultaneous radiofrequency ablation for treatment of adrenal metastases from hepatocellular carcinoma

Variable

TACE+RFA

TACE

χ2/t

P

Age, years

54.2 ± 9.3

56.8 ± 8.8

1.108

0.272

Gender

  

0.092

0.762

 M

26 (68.4%)

18 (72.0%)

  

 F

12 (31.6%)

7 (28.0%)

  

Child-Pugh grade

  

0.076

0.783

 A

30 (78.9%)

19 (76.0%)

  

 B

8 (21.1%)

6 (24.0%)

  

ECOG

  

0.406

0.523

 0

33 (86.8%)

23 (92.0%)

  

 1

5 (13.2%)

2 (8.0%)

  

Outcome of primary tumor

  

0.834

0.933

 Resection

9 (23.7%)

5 (20.0%)

  

 CRa

17 (44.7%)

12 (48.0%)

  

 PR

7 (18.4%)

5 (20.0%)

  

 SD

1 (2.6%)

0

  

 PD

4 (10.5%)

3 (12.0%)

  

Extra-adrenal metastases

  

1.638

0.440

 None

16 (42.1%)

7 (28.0%)

  

 One organ metastases

14 (36.8%)

13 (52.0%)

  

 Multiple organ metastases

8 (21.1%)

5 (20.0%)

  

AM location

  

0.118

0.731

 Unilateral

29 (76.3%)

20 (80.0%)

  

  Left

11 (28.9%)

11 (44.0%)

  

  Right

18 (47.4%)

9 (36.0%)

  

 Bilateral

9 (23.7%)

5 (20.0%)

  

Maximal diameter of AM(cm)

  

0.414

0.519

  ≥ 3

11 (23.4%)

9 (30.0%)

  

 <3

36 (76.6%)

21 (70.0%)

  

Tumor size of AM(cm)

    

 Range

1.5~ 7.3

1.2~ 8.1

  

 Mean

3.3 ± 1.6

3.5 ± 1.7

0.473

0.637

  1. Abbreviations: ECOG Eastern Cooperative Oncology Group, CR complete remission, PR partial remission, SD stable disease, PD progressive disease, AM adrenal metastasis
  2. Note aAssessed according to the mRECIST